Morgan Stanley Cullinan Oncology, Inc. Transaction History

Morgan Stanley

$1.39 Trillion
Q4 2024

A detailed history of Morgan Stanley transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Morgan Stanley holds 638,069 shares of CGEM stock, worth $5.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

638,069

Previous 673,372 5.24%

Holding current value

$5.1 Million

Previous $11.3 Million 31.06%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$10.77 - $17.6 $380,213 - $621,332	-35,303 Reduced 5.24%	638,069 $7.77 Million
Q3 2024 Nov 14, 2024	SELL	$16.03 - $20.86 $2.64 Million - $3.44 Million	-164,911 Reduced 19.67%	673,372 $11.3 Million
Q2 2024 Oct 17, 2024	SELL	$15.63 - $29.35 $4.91 Million - $9.23 Million	-314,361 Reduced 27.27%	838,283 $14.6 Million
Q2 2024 Aug 14, 2024	SELL	$15.63 - $29.35 $4.91 Million - $9.23 Million	-314,361 Reduced 27.27%	838,283 $14.6 Million
Q1 2024 Oct 17, 2024	BUY	$10.17 - $19.02 $3.2 Million - $5.98 Million	314,361 Added 37.5%	1,152,644 $19.6 Million
Q1 2024 Aug 16, 2024	BUY	$10.17 - $19.02 $2.37 Million - $4.43 Million	232,745 Added 25.3%	1,152,644 $19.6 Million
Q1 2024 May 15, 2024	BUY	$10.17 - $19.02 $2.37 Million - $4.43 Million	232,745 Added 25.3%	1,152,644 $19.6 Million
Q4 2023 Aug 16, 2024	BUY	$7.89 - $10.23 $643,950 - $834,931	81,616 Added 9.74%	919,899 $9.37 Million
Q4 2023 Feb 13, 2024	BUY	$7.89 - $10.23 $5.02 Million - $6.51 Million	636,483 Added 224.58%	919,899 $9.37 Million
Q3 2023 Nov 15, 2023	SELL	$9.05 - $11.72 $377,122 - $488,384	-41,671 Reduced 12.82%	283,416 $2.56 Million
Q2 2023 Aug 14, 2023	BUY	$8.8 - $13.4 $1.4 Million - $2.13 Million	159,139 Added 95.9%	325,087 $3.5 Million
Q1 2023 May 15, 2023	SELL	$10.2 - $11.91 $602,514 - $703,523	-59,070 Reduced 26.25%	165,948 $1.7 Million
Q4 2022 Feb 14, 2023	SELL	$9.72 - $13.62 $614,906 - $861,628	-63,262 Reduced 21.94%	225,018 $2.37 Million
Q3 2022 Nov 14, 2022	SELL	$11.82 - $15.42 $676,848 - $882,995	-57,263 Reduced 16.57%	288,280 $3.7 Million
Q2 2022 Oct 27, 2022	SELL	$7.31 - $13.55 $1.11 Million - $2.06 Million	-152,332 Reduced 30.6%	345,543 $4.43 Million
Q2 2022 Aug 15, 2022	SELL	$7.31 - $13.55 $1.11 Million - $2.06 Million	-152,332 Reduced 30.6%	345,543 $4.43 Million
Q1 2022 Oct 27, 2022	BUY	$10.47 - $16.75 $1.59 Million - $2.55 Million	152,332 Added 44.08%	497,875 $5.21 Million
Q1 2022 May 13, 2022	BUY	$10.47 - $16.75 $1.76 Million - $2.82 Million	168,419 Added 51.12%	497,875 $5.21 Million
Q4 2021 Feb 14, 2022	BUY	$15.36 - $25.0 $3.97 Million - $6.47 Million	258,657 Added 365.34%	329,456 $5.08 Million
Q3 2021 Nov 15, 2021	BUY	$22.56 - $29.68 $1.6 Million - $2.1 Million	70,799 New	70,799 $1.6 Million

Others Institutions Holding CGEM

# of Institutions

153

Shares Held

67.1M

Call Options Held

41.1K

Put Options Held

112K

View Full List

About Cullinan Oncology, Inc.

Ticker CGEM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,612,200
Market Cap $365M
Description
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...

More about CGEM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account